Review: Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients

Poordad, Fred; Landaverde, Carmen

doi:10.1177/1756283x08101217

Cited by 4 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, when patients were divided in the same way as in Hamdi et al's study (15), their results were confirmed (data not shown). Additionally, the p53 expression level was compared between RVRs (strong positive predictor for SVR) (9,37) and non-RVRs, as well as between NRs (strong negative predictor for SVR) (5) and non-NRs to confirm the lack of usefulness of p53 expression in predicting the response to anti-HCV therapy (data not shown). The association between p53 expression and the response to anti-HCV treatment was analyzed by Loguercio et al (22) at the protein level in liver samples.…”

Section: Discussionmentioning

confidence: 99%

HCV Infection and Interferon-Based Treatment Induce p53 Gene Transcription in Chronic Hepatitis C Patients

Świątek-Kościelna

Kałużna

Januszkiewicz‐Lewandowska

et al. 2015

Viral Immunology

View full text Add to dashboard Cite

It is suggested that the tumor suppressor p53 gene, classified as an interferon-stimulated gene, is implicated in the interferon (IFN)-mediated innate immunity against viruses. This study aimed to examine the transcriptional response of the p53 gene to hepatitis C virus (HCV) infection and IFN-based therapy in chronic hepatitis C (CHC) patients. The study included 65 CHC patients (HCV genotype 1), treated with pegylated IFN-α and ribavirin, and 51 healthy individuals. p53 gene expression was quantified by real-time polymerase chain reaction in peripheral blood mononuclear cells (PBMCs). Analyses were performed before and at weeks 4 and 12 of treatment. p53 gene expression was significantly upregulated in CHC patients compared with healthy controls and at week 4 of therapy. No significant differences in p53 mRNA expression between rapid virologic responders, complete early virologic responders, and nonresponders were observed. No significant correlation was found between p53 gene expression and viral load. The results obtained indicate that HCV infection and IFN-based treatment induces p53 gene transcription in PBMCs. The p53 gene may therefore play a role in HCV infection but is not directly involved in treatment-induced HCV elimination. Moreover, variations in p53 gene expression do not determine on-treatment response in patients with chronic HCV genotype 1 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

HCV Infection and Interferon-Based Treatment Induce p53 Gene Transcription in Chronic Hepatitis C Patients

Świątek-Kościelna

Kałużna

Januszkiewicz‐Lewandowska

et al. 2015

Viral Immunology

View full text Add to dashboard Cite

show abstract

“…In this respect, the presence of RVR is highly predictive of ultimate SVR with a full treatment course of 48 wk in genotype 1 patients [22] . In the current study, all genotype 1 patients (n = 7) who achieved RVR also attained SVR; while a study reported a SVR rate of 86.8% in patients with RVR [15] .…”

Section: Discussionmentioning

confidence: 95%

Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C

Rao

Koshy

Philip

et al. 2014

WJH

View full text Add to dashboard Cite

AIM:To study the safety and efficacy of pegylated interferon alfa-2b, indigenously developed in India, plus ribavirin in treatment of hepatitis C virus (HCV). METHODS:One-hundred HCV patients were enrolled in an open-label, multicenter trial. Patients were treated with pegylated interferon alfa-2b 1.5 μg/kg per week subcutaneously plus oral ribavirin 800 mg/d for patients with genotypes 2 and 3 for 24 wk. The same dose of peginterferon plus weight-based ribavirin (800 mg/d for ≤ 65 kg; 1000 mg/d for > 65-85 kg; 1200 mg/d for > 85-105 kg; 1400 mg/d for > 105 kg body weight) was administered for 48 wk for patients with genotypes 1 and 4. Serological and biochemical responses of patients were assessed. RESULTS:Eighty-two patients (35 in genotypes 1 and 4 and 47 in 2 and 3), completed the study. In genotype 1, 25.9% of patients achieved rapid virologic response (RVR): while the figures were 74.1% for early virologic response (EVR) and 44.4% for sustained virologic response (SVR). For genotypes 2 and 3, all patients bar one belonged to genotype 3, and of those, 71.4%, 87.5%, and 64.3% achieved RVR, EVR, and SVR, respectively. In genotype 4, 58.8%, 88.2%, and 52.9% of patients achieved RVR, EVR, and SVR, respectively. The majority of patients attained normal levels of alanine aminotransferase by 4-12 wk of therapy. Most patients showed a good tolerance for the treatment, although mild-to-moderate adverse events were exhibited; only two patients discontinued the study medication due to serious adverse events (SAEs). Eleven SAEs were observed in nine patients; however, only four SAEs were related to study medication. CONCLUSION:Peginterferon alfa-2b, which was developed in India, in combination with ribavirin, is a safe and effective drug in the treatment of HCV.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Hepatitis C virus; Genotype; Peginterferon alfa-2b; Ribavirin; Treatment Core tip: In a multicenter study, the safety and efficacy of pegylated interferon alfa-2b, indigenously developed CLINICAL TRIALS STUDYSubmit a

show abstract

“…In contrast to IL28B genotype, absolute lymphocyte counts and the fall in viral load are both continuous variables determined by the patient history and response -particularly at week 1 when these data were particularly influential in our model. Several previous reports suggest that rapid virological response or viral response within two weeks of starting treatment are stronger predictors of SVR [29,30] than even a ≥ 2-log 10 decrease in HCV RNA, low-level detectable HCV RNA at week 4 or an undetectable level by week 12 of therapy [19,31,32]. The current study indicates that a viral load fall of either 80% at week 1, or 90% at week 2 appears to be a better predictor of response than viral load itself.…”

Section: Discussionmentioning

confidence: 99%

Ribavirin Concentrations, Laboratory Variables, and Clinical Outcomes During Treatment of Hepatitis C Infection with First Generation Direct-Acting Antivirals

Michur¹,

Morgan²,

Carey³

et al. 2019

EJCBS

View full text Add to dashboard Cite

In treating hepatitis C infection, identification of reliable markers predicting virological non-response appear central to improving outcome and to prompting changes in dynamic treatment approaches. The interrelationship of ribavirin (RBV) concentrations and laboratory variables with clinical outcomes was evaluated in HCV patients treated with ribavirin, and with or without early direct acting antivirals (DAA). Correlations between RBV concentration, laboratory variables (haemoglobin, absolute lymphocyte, platelet and neutrophil counts, serum creatinine and hepatitis C viral load) and patients' characteristics associated with sustained virological response (SVR) were investigated using multivariate analysis. The 76 patients studied all received interferon (INF) and RBV, with 37 additionally given Boceprevir or Telaprevir. Significant correlations were noted between week 1 RBV concentration and subsequent total exposure at weeks 2, 4 and 12 (P < 0.0001). RBV concentrations in excess of 1.0 mg/L (week 1) and 2.0 mg/L (week 2) provided targets for avoiding breakthrough (P < 0.05). SVR was greater in patients without cirrhosis (73.3% vs. 41.3%; P < 0.01). All patients with an absolute haemoglobin (Hb) fall >30 g/L (week 8) experienced higher SVR rates (P < 0.03). RBV concentrations above 2.7 mg/L at week 4 or later increased the likelihood of Hb falls >30 g/L. Six factors were predictive of SVR in univariate analysis, and three in multivariate analysis. There is an association between SVR and absolute lymphocyte count, IL-28B CC genotype, and HCV-RNA load fall at week 1 (>80%) or week 2 (>90%) in HCV patients treated with INF/RBV and early DAA.

show abstract

Review: Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients

Cited by 4 publications

References 17 publications

HCV Infection and Interferon-Based Treatment Induce p53 Gene Transcription in Chronic Hepatitis C Patients

HCV Infection and Interferon-Based Treatment Induce p53 Gene Transcription in Chronic Hepatitis C Patients

Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C

Ribavirin Concentrations, Laboratory Variables, and Clinical Outcomes During Treatment of Hepatitis C Infection with First Generation Direct-Acting Antivirals

Contact Info

Product

Resources

About